Cargando…

Fecal diagnostics in combination with serology: best test to establish STEC-HUS

BACKGROUND: In the majority of pediatric patients, the hemolytic–uremic syndrome (HUS) is caused by an infection with Shiga toxin-producing Escherichia coli (STEC), mostly serotype O157. It is important to discriminate between HUS caused by STEC and complement-mediated HUS (atypical HUS) due to diff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wijnsma, Kioa L., van Bommel, Sheila A. M., van der Velden, Thea, Volokhina, Elena, Schreuder, Michiel F., van den Heuvel, Lambertus P., van de Kar, Nicole C. A. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039220/ https://www.ncbi.nlm.nih.gov/pubmed/27240858 http://dx.doi.org/10.1007/s00467-016-3420-7

Ejemplares similares

Glyco-iELISA: a highly sensitive and unambiguous serological method to diagnose STEC-HUS caused by serotype O157
por: Wijnsma, Kioa L., et al.
Publicado: (2018)

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
por: Bouwmeester, Romy N., et al.
Publicado: (2021)

Risk Factors for Short- and Long-Term Outcomes in Children With STEC-HUS/D(+) HUS: A Single-Center Experience
por: VanSickle, Judith Sebestyen, et al.
Publicado: (2018)

Heme as Possible Contributing Factor in the Evolvement of Shiga-Toxin Escherichia coli Induced Hemolytic-Uremic Syndrome
por: Wijnsma, Kioa L., et al.
Publicado: (2020)

Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding
por: Volokhina, Elena, et al.
Publicado: (2012)

Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS)
por: Loos, Sebastian, et al.
Publicado: (2021)

A young girl with an unusual cause of acute kidney injury: Answers
por: Binkhorst, Mathijs, et al.
Publicado: (2015)

A young girl with an unusual cause of acute kidney injury: Questions
por: Binkhorst, Mathijs, et al.
Publicado: (2015)

A Moderate Decrease in ADAMTS13 Activity Correlates with the Severity of STEC-HUS
por: Emirova, Khadizha M., et al.
Publicado: (2023)

The Shiga Toxin Receptor Globotriaosylceramide as Therapeutic Target in Shiga Toxin E. coli Mediated HUS
por: Feitz, Wouter J. C., et al.
Publicado: (2021)

Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study
por: Bouwmeester, Romy N., et al.
Publicado: (2022)

Low C3 Serum Levels Predict Severe Forms of STEC-HUS With Neurologic Involvement
por: Netti, Giuseppe Stefano, et al.
Publicado: (2020)

Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective
por: ter Avest, Mendy, et al.
Publicado: (2022)

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
por: Wijnsma, Kioa Lente, et al.
Publicado: (2019)

Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort
por: Michels, Marloes A. H. M., et al.
Publicado: (2021)

Plasma exchange or immunoadsorption for recurrent focal segmental glomerulosclerosis: clear differences in vitro
por: Veissi, Susan T, et al.
Publicado: (2022)

Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2
por: Wijnsma, Kioa L., et al.
Publicado: (2017)

Shiga Toxin Selectively Upregulates Expression of Syndecan-4 and Adhesion Molecule ICAM-1 in Human Glomerular Microvascular Endothelium
por: Volokhina, Elena B., et al.
Publicado: (2020)

Involvement of Angiopoietin-2 and Tie2 Receptor Phosphorylation in STEC-HUS Mediated by Escherichia coli O104:H4
por: Lukasz, Alexander, et al.
Publicado: (2015)

An Atypical Case of Shiga Toxin Producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) in a Lung Transplant Recipient
por: Manière, Louis, et al.
Publicado: (2019)

Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS): diagnosis, surveillance and public-health management in England
por: Jenkins, Claire, et al.
Publicado: (2020)

Correction to: Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
por: Wijnsma, Kioa L., et al.
Publicado: (2019)

Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
por: Wijnsma, Kioa L., et al.
Publicado: (2018)

Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome
por: Westra, Dineke, et al.
Publicado: (2016)

Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy
por: Michels, Marloes A. H. M., et al.
Publicado: (2019)

Nephrotic syndrome in a dish: recent developments in modeling in vitro
por: Veissi, Susan, et al.
Publicado: (2019)

The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?
por: Michels, Marloes A. H. M., et al.
Publicado: (2018)

Challenges in diagnostic testing of nephritic factors
por: Michels, Marloes A. H. M., et al.
Publicado: (2022)

Mitochondrial Disease and the Kidney With a Special Focus on CoQ(10) Deficiency
por: Schijvens, Anne M., et al.
Publicado: (2020)

Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura
por: Oh, Jisu, et al.
Publicado: (2019)

Levamisole Modulation of Podocytes’ Actin Cytoskeleton in Nephrotic Syndrome
por: Veissi, Susan T., et al.
Publicado: (2023)

Metagenomic Characterization of the Human Intestinal Microbiota in Fecal Samples from STEC-Infected Patients
por: Gigliucci, Federica, et al.
Publicado: (2018)

STEC:O111-HUS complicated by acute encephalopathy in a young girl was successfully treated with a set of hemodiafiltration, steroid pulse, and soluble thrombomodulin under plasma exchange
por: Yada, Noritaka, et al.
Publicado: (2015)

Comparative Genomics to Delineate Pathogenic Potential in Non-O157 Shiga Toxin-Producing Escherichia coli (STEC) from Patients with and without Haemolytic Uremic Syndrome (HUS) in Norway
por: Haugum, Kjersti, et al.
Publicado: (2014)

Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire
por: Kimman, Merel L., et al.
Publicado: (2018)

Ongoing haemolytic uraemic syndrome (HUS) outbreak caused by sorbitol-fermenting (SF) Shiga toxin-producing Escherichia coli (STEC) O157, Germany, December 2016 to May 2017
por: Vygen-Bonnet, Sabine, et al.
Publicado: (2017)

Genetics and complement in atypical HUS
por: Kavanagh, David, et al.
Publicado: (2010)

538. Human neutrophil gelatinase-associated protein (N-gal) and proinflammatory cytokines as biomarkers of disease severity in children with Hemolyitic Uremic Syndrom (HUS) and Shigatoxin-producing E.coli (STEC) infection.
por: Toledano, Analía, et al.
Publicado: (2022)

Interactions of Shiga-like toxin with human peripheral blood monocytes
por: Geelen, Joyce M., et al.
Publicado: (2007)

Shiga toxin-producing Escherichia coli (STEC) isolated from fecal samples of African dromedary camels
por: Baschera, Melinda, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vhg3leeiuovfomp3j0cq45ka1l